ATE292633T1 - Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren - Google Patents
Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitorenInfo
- Publication number
- ATE292633T1 ATE292633T1 AT02756522T AT02756522T ATE292633T1 AT E292633 T1 ATE292633 T1 AT E292633T1 AT 02756522 T AT02756522 T AT 02756522T AT 02756522 T AT02756522 T AT 02756522T AT E292633 T1 ATE292633 T1 AT E292633T1
- Authority
- AT
- Austria
- Prior art keywords
- fatty acid
- acid oxidation
- piperazine derivatives
- oxidation inhibitors
- substituted piperazine
- Prior art date
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical class C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000007718 Stable Angina Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lubricants (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Paper (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30662101P | 2001-07-19 | 2001-07-19 | |
| PCT/US2002/022897 WO2003008411A1 (en) | 2001-07-19 | 2002-07-18 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292633T1 true ATE292633T1 (de) | 2005-04-15 |
Family
ID=23186103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02756522T ATE292633T1 (de) | 2001-07-19 | 2002-07-18 | Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6930111B2 (enExample) |
| EP (1) | EP1406898B1 (enExample) |
| JP (1) | JP2004537554A (enExample) |
| KR (1) | KR100919141B1 (enExample) |
| CN (1) | CN1533388A (enExample) |
| AT (1) | ATE292633T1 (enExample) |
| AU (1) | AU2008202958A1 (enExample) |
| CA (1) | CA2454059A1 (enExample) |
| DE (1) | DE60203623T2 (enExample) |
| DK (1) | DK1406898T3 (enExample) |
| ES (1) | ES2236557T3 (enExample) |
| HU (1) | HUP0402088A3 (enExample) |
| IL (1) | IL159897A0 (enExample) |
| MX (1) | MXPA04000565A (enExample) |
| NO (1) | NO327635B1 (enExample) |
| NZ (1) | NZ530705A (enExample) |
| PL (1) | PL368529A1 (enExample) |
| PT (1) | PT1406898E (enExample) |
| RU (1) | RU2300533C2 (enExample) |
| WO (1) | WO2003008411A1 (enExample) |
| ZA (1) | ZA200400404B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7001909B2 (en) * | 2001-07-19 | 2006-02-21 | Cv Therapeutics, Inc. | Substituted heterocyclic compounds |
| IL165304A0 (en) | 2002-05-21 | 2006-01-15 | Cv Therapeutics Inc | Method of treating diabetes |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| AU2003268064A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| CN1894241A (zh) | 2002-08-09 | 2007-01-10 | 阿斯利康(瑞典)有限公司 | 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑 |
| AU2003264018A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| EP1567525B1 (en) * | 2002-12-05 | 2007-06-27 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| EP1806346B1 (en) * | 2002-12-05 | 2009-07-22 | Cv Therapeutics, Inc. | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| ATE443058T1 (de) | 2003-01-03 | 2009-10-15 | Cv Therapeutics Inc | Substituierte heterozyklische verbindungen |
| JP2006515891A (ja) * | 2003-01-17 | 2006-06-08 | シーブイ・セラピューティクス・インコーポレイテッド | 循環器疾患の処置に有効な置換ヘテロ環化合物 |
| JP2007518677A (ja) * | 2003-06-23 | 2007-07-12 | シーブイ・セラピューティクス・インコーポレイテッド | 脂肪酸酸化インヒビターとしてのピペラジンおよびピペリジンのウレア誘導体 |
| KR20060124646A (ko) | 2003-12-18 | 2006-12-05 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물 |
| EP1699527A1 (en) | 2004-01-02 | 2006-09-13 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
| KR20070051305A (ko) * | 2004-09-08 | 2007-05-17 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 치환된 피페라진 화합물 및 지방산 산화 저해제로서의 이의용도 |
| CN101541331A (zh) | 2006-08-24 | 2009-09-23 | 沃克哈特研究中心 | 具有抗微生物活性的新颖大环内酯和酮内酯 |
| US8088920B2 (en) * | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| SMT201700147T1 (it) * | 2008-10-10 | 2017-05-08 | Vm Discovery Inc | Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie |
| MX2011012140A (es) * | 2009-05-14 | 2012-02-28 | Gilead Sciences Inc | Ranolazina para el tratamiento de problemas del snc. |
| JPWO2011115150A1 (ja) * | 2010-03-18 | 2013-07-04 | 興和株式会社 | ベンゾチアジン化合物の製造方法 |
| CN111285819A (zh) * | 2018-12-07 | 2020-06-16 | 江苏恩华药业股份有限公司 | 一种苯并噁唑类化合物及其应用 |
| WO2023023995A1 (zh) * | 2021-08-25 | 2023-03-02 | 苏州大学 | 一种防治心肌缺血后心功能衰竭的药物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1133989A (en) | 1964-12-08 | 1968-11-20 | Chugai Pharmaceutical Co Ltd | Theophylline derivatives, their salts and process for preparing the same |
| DE2834114A1 (de) * | 1978-08-01 | 1980-02-14 | Schering Ag | Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| JPS6137765A (ja) * | 1984-07-19 | 1986-02-22 | サンド・アクチエンゲゼルシヤフト | ３‐アミノプロポキシアリール誘導体 |
| US4723014A (en) * | 1986-11-19 | 1988-02-02 | Warner-Lambert Company | Process for the preparation of 2-substituted-1,4-dihydropyridines |
| DE3723648A1 (de) * | 1987-07-17 | 1989-01-26 | Sandoz Ag | Indol-derivate, ihre herstellung und sie enthaltende arzneimittel |
| JPH0699399B2 (ja) * | 1988-10-06 | 1994-12-07 | 三井東圧化学株式会社 | 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤 |
| JPH02268162A (ja) * | 1989-04-10 | 1990-11-01 | Fujisawa Pharmaceut Co Ltd | ジフェニルピリジン誘導体 |
| MX9308025A (es) * | 1992-12-22 | 1994-08-31 | Lilly Co Eli | Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene. |
| AU5170698A (en) * | 1996-11-14 | 1998-06-03 | American Home Products Corporation | Substituted tetrahydro-1,3,5-triazin-2{1h}-thiones as anti-atherosclerotic agents |
| HUP0202679A3 (en) * | 1999-09-13 | 2003-04-28 | Wyeth Corp | Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1h-indol-5-ols, process for their preparation and pharmaceutical compositions containing them |
| SE9904765D0 (sv) | 1999-12-23 | 1999-12-23 | Astra Ab | Pharmaceutically-useful compounds |
| US6677343B2 (en) | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6552023B2 (en) | 2000-02-22 | 2003-04-22 | Cv Therapeutics, Inc. | Aralkyl substituted piperazine compounds |
| WO2001062711A2 (en) * | 2000-02-22 | 2001-08-30 | Cv Therapeutics, Inc. | Substituted alkylene diamine compounds |
| EP1259493A2 (en) * | 2000-02-22 | 2002-11-27 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| US6451798B2 (en) | 2000-02-22 | 2002-09-17 | Cv Therapeutics, Inc. | Substituted alkyl piperazine derivatives |
| SE0003795D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Pharmaceutically useful compounds |
| US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
-
2002
- 2002-07-18 IL IL15989702A patent/IL159897A0/xx unknown
- 2002-07-18 JP JP2003513970A patent/JP2004537554A/ja not_active Ceased
- 2002-07-18 NZ NZ530705A patent/NZ530705A/en not_active IP Right Cessation
- 2002-07-18 MX MXPA04000565A patent/MXPA04000565A/es active IP Right Grant
- 2002-07-18 DE DE60203623T patent/DE60203623T2/de not_active Expired - Fee Related
- 2002-07-18 AT AT02756522T patent/ATE292633T1/de not_active IP Right Cessation
- 2002-07-18 DK DK02756522T patent/DK1406898T3/da active
- 2002-07-18 KR KR1020047000898A patent/KR100919141B1/ko not_active Expired - Fee Related
- 2002-07-18 PT PT02756522T patent/PT1406898E/pt unknown
- 2002-07-18 RU RU2004104951/04A patent/RU2300533C2/ru not_active IP Right Cessation
- 2002-07-18 EP EP02756522A patent/EP1406898B1/en not_active Expired - Lifetime
- 2002-07-18 CA CA002454059A patent/CA2454059A1/en not_active Abandoned
- 2002-07-18 US US10/198,237 patent/US6930111B2/en not_active Expired - Fee Related
- 2002-07-18 WO PCT/US2002/022897 patent/WO2003008411A1/en not_active Ceased
- 2002-07-18 ES ES02756522T patent/ES2236557T3/es not_active Expired - Lifetime
- 2002-07-18 PL PL02368529A patent/PL368529A1/xx not_active Application Discontinuation
- 2002-07-18 HU HU0402088A patent/HUP0402088A3/hu unknown
- 2002-07-18 CN CNA02814371XA patent/CN1533388A/zh active Pending
-
2004
- 2004-01-19 NO NO20040234A patent/NO327635B1/no not_active IP Right Cessation
- 2004-01-19 ZA ZA200400404A patent/ZA200400404B/en unknown
-
2008
- 2008-07-03 AU AU2008202958A patent/AU2008202958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20030181352A1 (en) | 2003-09-25 |
| KR20040029374A (ko) | 2004-04-06 |
| NO327635B1 (no) | 2009-09-07 |
| HUP0402088A3 (en) | 2010-03-29 |
| AU2002322527A2 (en) | 2003-03-03 |
| PL368529A1 (en) | 2005-04-04 |
| RU2300533C2 (ru) | 2007-06-10 |
| US6930111B2 (en) | 2005-08-16 |
| MXPA04000565A (es) | 2005-06-17 |
| EP1406898A1 (en) | 2004-04-14 |
| AU2002322527B2 (en) | 2008-04-17 |
| DE60203623D1 (de) | 2005-05-12 |
| WO2003008411A1 (en) | 2003-01-30 |
| HK1064374A1 (en) | 2005-01-28 |
| CN1533388A (zh) | 2004-09-29 |
| ES2236557T3 (es) | 2005-07-16 |
| RU2004104951A (ru) | 2005-06-27 |
| DE60203623T2 (de) | 2006-01-19 |
| NZ530705A (en) | 2005-08-26 |
| HUP0402088A2 (hu) | 2005-02-28 |
| NO20040234L (no) | 2004-03-18 |
| AU2008202958A1 (en) | 2008-07-31 |
| KR100919141B1 (ko) | 2009-09-25 |
| DK1406898T3 (da) | 2005-05-30 |
| IL159897A0 (en) | 2004-06-20 |
| PT1406898E (pt) | 2005-08-31 |
| JP2004537554A (ja) | 2004-12-16 |
| CA2454059A1 (en) | 2003-01-30 |
| EP1406898B1 (en) | 2005-04-06 |
| ZA200400404B (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE292633T1 (de) | Substituierte piperazinderivate und ihre verwendung als fettsaüreoxidationsinhibitoren | |
| NO20054969L (no) | 2-cyanopropansyreamid- og esterderivater og deres anvendelse | |
| DE60238747D1 (de) | Acylierte 1,2,3,4-tetrahydronaphthylamine und deren verwendung als pharmazeutika | |
| ATE311380T1 (de) | Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren | |
| ATE411288T1 (de) | Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) | |
| NO20051965L (no) | Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander. | |
| EA200100826A1 (ru) | 16-галогенопроизводные эпотилона, способ их получения и их применение в фармацевтике | |
| ATE440087T1 (de) | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen | |
| ATE301640T1 (de) | Anellierte 4-carboxyamino-2-methyl-1,2,3,4- tetrahydrochinoline als cetp-hemmer | |
| BR0114045A (pt) | Poliarilcarboxamidas úteis como agentes redutores de lipìdeos | |
| EA200200390A1 (ru) | Новые оксабиспидиновые соединения, полезные при лечении сердечных аритмий | |
| DE60105419D1 (de) | Serinprotease-inhibitoren | |
| DE60306548D1 (de) | Substituierte 3-carbonyl-1-yl essigsäure derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren | |
| SE0100326D0 (sv) | New compounds | |
| MXPA02012910A (es) | Amidas de acidobifenilcarboxilico, su preparacion y su uso como medicinas. | |
| ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
| DE69813565D1 (de) | Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung | |
| DE60328545D1 (de) | Substituierte Piperazinderivate und ihre Verwendung als Inhibitoren der Fettsäureoxidation | |
| HUP0102057A2 (hu) | Benzofuroxánszármazékok alkalmazása angina pectoris kezelésében | |
| DE60200135D1 (de) | 4-(2-Pyridyl)piperazine als Agonisten des 5HT7 Rezeptors | |
| WO2004067506A3 (en) | Substituted heterocyclic compounds | |
| BR0108592A (pt) | Compostos de piperazina substituìda | |
| DE60329323D1 (de) | Substituierte heterozyklische verbindungen | |
| WO2006029179A3 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| SE0002603D0 (sv) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1406898 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |